Hepamerz%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252528l-Ornithine%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520l-Aspartate%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520-%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520lola%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252529

## Hepamerz (L-Ornithine L-Aspartate) ### Overview Hepamerz is a combination of two amino acids, L-ornithine and L-aspartate. It is thought to reduce elevated ammonia levels in the blood by promoting the urea cycle and glutamine synthesis in the liver. ### Primary Indications * Treatment of latent and manifest hepatic encephalopathy associated with hyperammonemia. ### Adult Dosing * **Hepatic Encephalopathy:** 3 to 6 grams orally three times daily, or 5 grams intravenously daily. The total daily dose should not exceed 18 grams orally or 5 grams intravenously. Treatment duration is individualized. ### Pediatric Dosing * There is **limited data** on pediatric use. Dosing should be individualized by a specialist based on clinical response and tolerance. ### Dose Adjustments * **Renal Impairment:** No specific dose adjustments are established, but caution is advised due to potential accumulation of amino acids. * **Hepatic Impairment:** This drug is intended for patients with hepatic impairment; no dose adjustments are typically needed for the liver condition itself, but careful monitoring is essential. ### Contraindications * Severe renal insufficiency (creatinine clearance < 25 mL/min). * Known hypersensitivity to L-ornithine, L-aspartate, or any component of the formulation. * Hyperornithinemia-Congenital hyperammonemia. ### Adverse Effects * **Common:** Gastrointestinal disturbances such as nausea, vomiting, abdominal pain, diarrhea, and bloating. * **Less Common:** Dizziness, headache, fatigue, skin rash. ### Key Drug Interactions * **Barbiturates and Hypnotics:** May potentially antagonize the effects of these medications. * **Diuretics:** May increase the risk of electrolyte imbalances. ### Monitoring * **Ammonia Levels:** Monitor serum ammonia levels, particularly at the initiation of therapy and if clinical signs of encephalopathy change. * **Renal Function:** Monitor renal function, especially in patients with pre-existing renal impairment. * **Electrolytes:** Monitor serum electrolytes. * **Clinical Symptoms:** Assess for improvements in neurological status and symptoms of hepatic encephalopathy. ### Clinical Pearls * The intravenous formulation is generally reserved for more severe cases or when oral administration is not feasible. * Treatment duration is guided by clinical response and patient tolerance. * Ensure adequate hydration, especially with intravenous administration. *** *This information is intended for healthcare professionals. Always consult the most current prescribing information and guidelines for definitive patient care decisions. Dosing and indications may vary based on local protocols and individual patient factors.*